Zevra Therapeutics (NASDAQ:ZVRA) Issues Quarterly Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) issued its earnings results on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14, FiscalAI reports. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The business had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• Second-quarter revenue rose 53% year over year to $39.7 million, driven by $30.2 million in U.S. MIPLYFFA sales, which increased 23% sequentially and 40% year over year.
• MIPLYFFA enrollment reached 184 prescription forms through June 30, including 23 in the first half of 2026, with a diverse mix of newly and previously diagnosed patients, children and adults, and specialty-center and community-practice prescribers.
• Zevra requested an EMA re-examination of arimoclomol’s negative CHMP opinion and expects a decision in the fourth quarter; management cited long-term, pediatric, expanded-access, and safety data as support, but approval remains uncertain.
• Celiprolol’s Phase III DISCOVER trial remains early and event-driven, with 66 of 150 patients enrolled and only three confirmed events versus the 28 needed for interim analysis, prompting efforts to accelerate enrollment and regulatory discussions.
• Cash, cash equivalents, and investments totaled $260.2 million at quarter-end, up approximately $23.4 million sequentially, giving Zevra flexibility to fund MIPLYFFA expansion, celiprolol, and potential external opportunities without relying on capital markets.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded up $0.01 during midday trading on Wednesday, reaching $10.53. 776,877 shares of the company’s stock were exchanged, compared to its average volume of 1,361,412. The firm’s 50 day simple moving average is $12.32 and its two-hundred day simple moving average is $10.54. The stock has a market cap of $622.53 million, a price-to-earnings ratio of 5.29 and a beta of 0.91. Zevra Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $15.03.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in Zevra Therapeutics by 9.6% during the fourth quarter. Millennium Management LLC now owns 1,134,358 shares of the company’s stock worth $10,164,000 after buying an additional 99,107 shares during the period. Man Group plc lifted its holdings in shares of Zevra Therapeutics by 174.4% in the 4th quarter. Man Group plc now owns 92,347 shares of the company’s stock worth $827,000 after acquiring an additional 58,695 shares during the last quarter. Engineers Gate Manager LP boosted its position in shares of Zevra Therapeutics by 23.4% during the 4th quarter. Engineers Gate Manager LP now owns 44,020 shares of the company’s stock worth $394,000 after purchasing an additional 8,359 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Zevra Therapeutics during the 4th quarter worth approximately $124,000. Finally, AQR Capital Management LLC increased its holdings in Zevra Therapeutics by 18.9% in the 4th quarter. AQR Capital Management LLC now owns 181,129 shares of the company’s stock valued at $1,623,000 after purchasing an additional 28,818 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analysts Set New Price Targets

ZVRA has been the subject of a number of analyst reports. Maxim Group upped their price objective on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings downgraded shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. BTIG Research decreased their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.86.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.